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Background: microRNAs (miRNAs) are important regulators of translation and have been implicated in the
pathogenesis of a number of cardiovascular diseases, including stroke, and suggested as possible prognostic
biomarkers. Our aim was to identify miRNAs that are differentially regulated in cerebral arteries after subarachnoid
hemorrhage (SAH), using a rat injection model of SAH and a qPCR-based screen of 728 rat miRNAs. Additionally,
serum was analyzed for a possible spill-over to the circulation of regulated miRNAs from the vessel walls.
Results: We identified 482 different miRNAs expressed in cerebral arteries post-SAH. Two miRNAs, miR-30a and
miR-143, were significantly upregulated in cerebral arteries after SAH when compared to sham-operated animals.
However, none of these exhibited significantly altered serum levels after SAH versus post-sham surgery. The most
robust upregulation was seen for miR-143, which has several predicted targets and is a strong regulator of vascular
morphology. We hypothesize that miR-30a and miR-143 may play a role in the vascular wall changes seen
after SAH.
Conclusions: We report that miR-30a and miR-143 in the cerebral arteries show significant changes over time
after SAH, but do not differ from sham-operated rats at 24 h post-SAH. Although this finding suggests interesting
novel possible mechanisms involved in post-SAH cerebrovascular changes, the lack of regulation of these miRNAs in
serum excludes their use as blood-borne biomarkers for cerebrovascular changes following SAH.
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Stroke is a leading cause of death and disability world-
wide, and stroke patients have a case fatality risk that is
approximately three times higher than that of patients
who suffer a coronary infarct. Subarachnoid hemorrhage
(SAH) is a type of stroke associated with vasospasm, late
cerebral ischemia (LCI), and a high death rate [1]. We
have found that LCI correlates with upregulation of con-
tractile receptors and inflammation in brain vessels and
that these changes rely on enhanced transcription and
translation of specific genes in the vascular smooth
muscle cells of cerebral arteries [2].* Correspondence: anne.holt.mueller@regionh.dk
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transcripts that are not translated into proteins but in-
stead regulate the stability and translation of protein-
coding transcripts. The most studied of these are the
microRNAs (miRNAs), consisting of 19–24 nucleotides.
miRNAs modulate gene expression through both mRNA
degradation and translational repression mechanisms,
and miRNA–mRNA regulatory networks are highly
complex [3]. Mature miRNAs are incorporated into the
RNA-induced silencing complex (RISC), where they can
bind to their target mRNA [4]. This binding may result
in inhibition of translation or deadenylation of the
mRNA and thus promotion of degradation [5]. Studies
have also suggested that miRNAs can target promoter
regions and induce gene expression [6]. Each miRNA
might have hundreds of targets and the potential toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and the immune response [8]. miRNAs are expressed at
different levels in different cell types, and these levels
change under pathological conditions [9].
miRNAs also play an important role in regulating vas-
cular smooth muscle phenotype by maintaining or inhi-
biting differentiation [10]. Furthermore, miRNAs are
thought to be involved in the pathophysiology of differ-
ent forms of stroke. In rats, blood and cortical miRNA
levels change dramatically after experimental focal ische-
mic stroke [11] and after intracerebral hemorrhage [12].
In ischemic stroke patients, the levels of certain miRNAs
in the blood are associated with clinical outcome [13].
Some of the highly expressed miRNAs in post-stroke
brain tissue can be detected in the peripheral blood
[12,14], indicating that brain-specific miRNAs could
serve as blood-borne biomarkers for brain ischemia [15].
In the case of SAH, there is an unmet need for blood-
borne biomarkers for predicting risk of cerebral vaso-
spasm and LCI.
A series of earlier studies demonstrated a number of
expressional changes in cerebral arteries after different
types of stroke, such as focal cerebral ischemia [16] and
SAH [17], and after cardiac arrest [18]. We have shown
that activation of specific signal transduction pathways
in the cerebral vasculature after stroke leads to transcrip-
tional regulation of vasoconstrictor receptors, inflamma-
tory mediators, and proteins involved in maintaining
blood–brain barrier integrity [19]. However, regulation
likely also occurs at other levels, and we hypothesize that
SAH leads to changes in miRNAs in cerebral arteries and
that these miRNAs are secreted into serum where they
may serve as biomarkers for predicting risk of cerebral
vasospasm and LCI.
Thus, the aim of this study was to examine and
characterize changes in miRNA levels in cerebral vessels
from rats after experimental SAH as compared to sham-
operated animals, and to establish if altered miRNA
levels are detectable in serum. We report that miR-30a,
involved in regulation of angiogenesis, and miR-143, cor-
related to vascular smooth muscle tone regulation, are
significantly regulated after SAH.
Results
Experimental SAH
For the miRNAome screening, three groups of animals
were subjected to experimental SAH and terminated at
different time points (1 h, 6 h, and 24 h) after surgery. A
fourth group of animals was subjected to sham oper-
ation, and terminated at 24 h post-surgery, and used as
controls. For the technical confirmation part of the study
and for serum investigations, a fifth group of animals,
termed 0 h, was also included; these animals were termi-
nated immediately after injection of blood. Each groupcontained four replicates, and each replicate consisted of
tissue pooled from two animals; i.e., eight animals were
used for each group. During SAH surgery, intracranial
pressure (ICP) went from 4–8 mmHg to 80–100 mmHg
following injection of blood. The cortical blood flow was
reduced by a minimum of 75% and remained low for a
minimum of 5 min after blood injection. In addition, a
Cushing effect was observed in all animals. These
physiological parameters of experimental SAH reached
values similar to those we have previously described [20]
and did not differ between the groups.
miRNAome screening of large cerebral arteries
The initial screen of 728 rat miRNAs from cerebral ves-
sels demonstrated that 482 miRNAs were expressed
in both sham and SAH rats at 1, 6, and 24 h post-
operation (Additional file 1). The overall analysis of the
data from the initial screen revealed differences in
miRNA expression between sham-operated animals and
animals at the early stages of SAH (1 h and 6 h post-
SAH). Hierarchical clustering analysis showed that sam-
ples from sham-operated animals and 24-h SAH animals
clustered together and that samples from 1-h and 6-h
SAH animals clustered away from samples from the
late time point (24 h post-SAH) (Figure 1). Of the 482
miRNAs that were expressed in both sham-operated ani-
mals and animals subjected to SAH, we found that 4
miRNAs (miR-30a, miR-143, miR-191*, and miR-223)
showed statistically significant changes in expression be-
tween the experimental groups (Table 1).
Confirmation of regulation of miRNA levels in
cerebral arteries
Subsequent technical confirmation of the data with
additional qPCR assays confirmed that miR-30a and
miR-143 exhibited significantly altered expression levels
after SAH when compared to sham animals (Figure 2).
miR-30a and miR-143 were both significantly upregu-
lated at 1 h and 6 h post-SAH as compared to sham.
The increases were approximately 2-fold for miR-30a at
both time points and 3- and 4-fold, respectively, for
miR-143. For both miR-30a and miR-143, the SAH-
induced upregulation appeared to be transient because
expression levels at 24 h post-SAH did not differ from
sham. The other two miRNAs identified in the miRNA
screen, miR-191* and miR-223, showed no significant
differences in expression between the sham and the
other groups (Figure 2).
We also examined the regulation of miR-145 because
of its relationship with miR-143 and because many stud-
ies have shown that the two often co-transcribe and are
important in the phenotype of vascular smooth muscle
cells [10,21]. However, we could not demonstrate any
regulation of miR-145 in this study (Figure 2E).
Figure 1 Cerebral arterial miRNAs expressed after SAH. Hierarchical cluster analysis of miRNAs expressed in large cerebral arteries of rats
subjected to SAH for 1 h, 6 h, or 24 h or to sham surgery. The later time points (24 h post-SAH or post-sham) cluster together and away from the
early time points (1 h and 6 h post-SAH). Red indicates high expression and green low expression.
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As mentioned previously, miRNAs have been suggested
as potential disease biomarkers because they can be de-
tected in peripheral blood [13]. To examine the potential
use of miRNAs as biomarkers for cerebrovascular path-
ology after SAH, possible spill-over of regulated miRNAs
from cerebral arteries into the bloodstream was investi-
gated. Total blood was obtained from rats subjected to
experimental SAH and sham surgery, and the miRNA
levels of 12 selected candidate miRNAs including miR-
30a, miR-143, and miR-223 were measured along with 9
controls for normalization (Table 2). The candidates
were selected based on the initial screen of miRNA ex-
pression in cerebral arteries and on previous findings.
miR-145, miR-221, and miR-222 were selected based on
their relationship with miR-143 and miR-223, respect-
ively. miR-133a was chosen because of its known in-
volvement in controlling the phenotypic switch inTable 1 Cerebral arterial miRNAs significantly changed
after SAH
1 h 6 h 24 h ANOVA p-value
miR-30a 0.5 ± 0.07 2.0 ± 0.5 0.6 ± 0.05 0.005
miR-143 0.1 ± 0.01 16.3 ± 4.8 0.7 ± 0.5 0.001
miR-191* 6.3 ± 2.0 10.2 ± 3.0 6.5 ± 1.8 0.04
miR-223 5.4 ± 1.3 0.7 ± 0.05 1.7 ± 0.9 0.02
Fold changes over sham in large cerebral arteries for miR-30a, miR-143, miR-191*,
and miR-223 at 1 h, 6 h, and 24 h post-SAH. Data from the miRNAome screen were
analyzed using the 2–ΔCt quantitative method and one-way ANOVA. Of the 482
miRNAs expressed in both SAH and sham animals, the 4 miRNAs listed in this table
showed significantly different expression levels between the groups. The p values
from the ANOVA analyses are in the right column.vascular smooth muscle cells [22,23]. miR-21, a marker
of vascular smooth muscle cell proliferation and apop-
tosis, was also included along with miR-126, an endothe-
lial marker, and miR-320, which is linked to ischemia
and infarction [24-26].
Because the 0 h and 1 h post-SAH time points are of
little relevance in a biomarker setting, we focused on
miRNA levels in serum at 6 h and 24 h post-SAH, when
a biomarker would be therapeutically relevant. None of
the investigated miRNAs showed significant changes in
serum levels at these time points when compared to
sham (data not shown), and the increased levels of miR-
30a and miR-143 found in the arteries post-SAH were
thus not reflected in serum levels.
Discussion
The present study is the first demonstration of a time-
dependent change in the expression of miR-30a and
miR-143 in large cerebral arteries after experimental
SAH in rats. This finding adds important information to
our current knowledge of the vascular events that occur
in cerebral arteries following acute SAH. We used a
screening method to assess the whole rat miRNAome to
identify as many miRNAs as possible in an un-biased
setting (n = 728). This choice made it possible to identify
four miRNAs that were differentially expressed in cere-
bral arteries between the experimental groups. Subse-
quent additional qPCR assays confirmed the changes
identified for miR-30a and miR-143, but not for miR-
191* and miR-223.
To investigate the time-course of changes in cerebro-
vascular miRNA expression after SAH, we conducted
Figure 2 Confirmation of differential miRNA expression. To confirm the differential expression of miR-30a, miR-143, miR-191*, and miR-223 in
SAH and sham animals as well as the lack of differential expression of miR-145, additional qPCR assays were performed. Fold changes over sham
were calculated using the 2–ΔΔCt quantitative method and analyzed with Student’s t-tests. The differential expression of miR-191* and miR-223
could not be confirmed. Fold change over sham for miR-30a (A), miR-143 (B), miR-191* (C), miR-223 (D), and miR-145 (E) at 0 h, 1 h, 6 h, and
24 h post-SAH. Sham (white bars) is set to 1. * = p < 0.05, ** = p < 0.01, compared to sham.
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the results to those for sham-operated animals. In the
current study only one group of sham-operated animals
were included, i.e. rats that were terminated 24 h after
sham surgery. It could be argued that sham groupsshould have been included for each time point in order
to strengthen the conclusion that the here presented
miRNA changes are indeed due to SAH and not surgery
per se. However, we believe that it is fair to assume that
for the applied SAH model the sham surgery does not














Serum was investigated for the potential spill-over of miRNA from the cerebral
arteries. The table shows selected candidate miRNAs (left column) and
normalizer miRNAs (right column). Candidate miRNAs identified in the initial
screen of miRNA expression in cerebral vessels are shown in italics.
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sumption is based on our previous research [27] where
there are no significant differences in mRNA levels of
IL6, STAT3 and JAK2 between animals subjected to
sham surgery for the SAH model used in our study and
terminated 6 h and 24 h after surgery. Additionally,
levels of phosphorylated STAT in sham-operated ani-
mals are equivalent in 6-h sham and 24-h sham animals
[28] and detailed analyses of mRNA changes of the three
housekeeping genes GAPDH, β-actin and EF-1 (elongat-
ing factor 1) in cerebral arteries after SAH [29-31] dem-
onstrated the same stable expression at all time points
studied (0, 1, 3, 6, 12, 24 and 48 hours).
At 6 h post-SAH, the miRNA changes were most pro-
nounced. At 24 h after SAH, miRNA levels had returned
to baseline and did not differ from values for corre-
sponding miRNA in sham-operated animals. miR-30a
and miR-143 both displayed upregulation in cerebral ar-
teries at 6 h after SAH. The role of the upregulation or
downregulation of a given miRNA depends on whether
it is positively or negatively regulating protein ex-
pression at the post-translational level by binding to
the 3’untranslated region of its target mRNA [3] or
acts by another mechanism, such as inducing expres-
sion by binding to specific promoter regions in the
nucleus [6].
The finding presented here is most intriguing because
miR-143 is highly expressed in vascular smooth muscle
cells, cardiac muscle, and endothelial cells and has been
identified as essential for regulating smooth muscle cell
proliferation and differentiation [32]. We have not dir-
ectly tested whether the observed changes in miR-143
expression after SAH are pathological or beneficial.However, the fact that miR-143 was identified in our
screen strengthens the confidence in this miRNA as an
important contributor to the vascular changes that occur
in conjunction with experimental SAH. Interestingly,
miR143/145 knockout mice are viable and fertile, but
they have a thinner arterial wall than the wild-type ani-
mals and thus significantly lower blood pressure [33].
Furthermore, neointima formation in response to vascu-
lar injury is profoundly impeded in mice lacking these
miRNAs [34]. In a conditional Dicer knockout mouse,
which do not have functional miRNAs, it was found that
miRNAs are essential for vascular smooth muscle cell
differentiation and function, a phenotype that can par-
tially be rescued by miR-145, again pointing to its crucial
role in vascular smooth muscle cells [32,35].
A hallmark and a concerning complication of SAH is
excessive cerebral vasoconstriction in the hours and days
after insult, with the development of LCI [36]. This
study suggests that an increase in miR-143 and in part
miR-145 in the hours after SAH could play an important
role in the early development of this pathology. How-
ever, this possibility needs to be investigated further in
studies in which, for instance, the effect of miR-143
antagomirs on vasoconstriction after SAH could be
evaluated.
The altered regulation of miR-30a is also of interest
because the miR-30 family is well studied but has not
previously been reported as being involved in vascular
changes after SAH. The miR-30 family members are
known for their role in angiogenesis-related myocardial
matrix remodeling via their interaction with connective
tissue growth factor [37].
Both miR-30a and miR-143 were upregulated in cere-
bral vessels after SAH; however, this regulation was not
detectable in the serum. Furthermore, none of the other
10 investigated miRNAs showed significant changes in
serum levels when compared to sham. Thus, none of the
12 candidate miRNAs show obvious potential as bio-
markers for cerebral vasospasm and LCI after SAH. The
cerebral vessels constitute a small amount of tissue com-
pared to other cell types, and miRNAs secreted from the
vessels after SAH might therefore be concealed by the
miRNAs secreted from more abundant tissues. Another
issue is the question of when or if the miRNAs can pass
the blood–brain barrier and enter the blood stream. In
general, miRNAs are small and might to some extent
pass the blood–brain barrier, whose integrity is main-
tained by a delicate cross-talk between cerebral endothe-
lial cells, junction proteins, and other cells of the
neurovascular unit. In fact, recent data have suggested
that miR-29b is involved in its regulation [38]. Even if
regulated miRNAs from brain and/or cerebrovascular
smooth muscle cells pass and in some cases possibly
modify the blood–brain barrier, the potential for these
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on our findings, very limited for SAH because the major
differences were seen early on (6 h post SAH) and nor-
malized fairly rapidly to the sham level.
Conclusion
The data from this miRNA screen in cerebral arteries of
rats following SAH suggest that in particular, miR-30a
and miR-143 changed with time but did not differ from
a control group of sham-operated rats at 24 h. Future
work with antagomirs will likely shed more light on the
involvement of miRNAs in cerebral vasospasm, vascular
inflammation, blood–brain barrier dysfunction, and de-
velopment of LCI after SAH.
Methods
Experimental subarachnoid hemorrhage
All animal experiments were approved by the Danish
Animal Experiments Inspectorate (license number: 2012-
15-2934-00389).
Rats were subjected to experimental SAH following
the model described by Prunell et al. [39]. Male Sprague–
Dawley rats (Taconic, Denmark) weighing 320 g were
anesthetized using 1.5% isoflurane (Baxter A/S, Denmark).
Two catheters were placed, one in the tail artery to meas-
ure blood pressure and one in the subarachnoid space
under the suboccipital membrane to measure the ICP. A
laser Doppler probe was used to measure local cortical
blood flow to ensure that the reduction in flow was of a
sufficient magnitude and duration. A 27G canula was
stereotactically inserted 6.5 mm anterior to the bregma at
the midline and lowered until it hit the base of the skull,
then retracted 1 mm. The rats were equilibrated for
15 min, and 250 μl blood was drawn from the tail catheter
and injected via the canula at a pressure equal to the mean
arterial blood pressure (80–100 mmHg). Only animals
that displayed a drop in flow of 75% that remained low
after a minimum of 5 min and a rise in ICP above mean
arterial blood pressure were included in the study. Rats in
the 0 h group were immediately drained of blood and eu-
thanized by decapitation. The rats in the other groups
were allowed to wake up and recover, and 7.5 mg/kg car-
profen (Rimadyl®, Pfizer) was administered subcutaneously
as analgesia. After 1 h, 6 h, or 24 h, the rats were anesthe-
tized by subcutaneous injection with 2.5 ml/kg of a
mixture of Hypnorm-Midazolam (1:1:2) in sterile water
(containing 0.079 mg/ml fentanyl, 2.50 mg/ml fluanisone,
Hypnorm®, VetaPharma Ltd, UK, and 1.25 mg/ml
Midazolam-Hameln, Hameln, Germany). Rats were
drained of blood by puncture of the ophthalmic venous
plexus with a capillary tube, and serum was obtained.
The rats were euthanized by decapitation, and the middle
cerebral arteries (MCAs) and the basilar artery were
dissected. Sham-operated rats underwent the sameprocedures as described above with the exception that no
blood was injected intracisternally. Injection of saline was
deliberately avoided because both the rise in ICP and the
injected blood contribute to SAH-induced effects in the
cerebral vasculature [20].
Rats were terminated at four time points (0 h, 1 h, 6 h,
and 24 h) after SAH. Each time point contained four
replicates, and each replicate consisted of tissue pooled
from two animals. Animals subjected to sham operation
were terminated at 24 h post-surgery and used as
controls.
RNA purification and qPCR
The MCAs and the basilar arteries of two animals were
pooled (approx. 10 mg tissue in total), and total RNA
was purified using a NucleoSpin miRNA kit (Macherey-
Nagel, Germany) as described by the manufacturer.
Tissue was pooled to extract a sufficient amount of RNA
(40 ng). The RNA integrity number (RIN) was deter-
mined with an Agilent RNA 6000 Nano Kit on a 2100
Bioanalyzer (Agilent, USA) and a minimum of 7 was set
as the inclusion criterion. Concentrations were deter-
mined with NanoDrop 2000c (Thermo Scientific, USA)
spectrophotometer measurements. RNA was converted
to cDNA using the Universal cDNA synthesis kit at
60 min at 42°C and 5 min at 95°C, and cooled to 4°C
(Exiqon, Denmark). The qPCR screen of the miRNAome
was performed with microRNA Ready-to-Use PCR
Mouse & Rat Panel I + II V2 R with primers for 752 ro-
dent miRNAs (728 of these are present in rat). This
screen is a qPCR screen that includes two 384-well
panels pre-coated with different primers in each well.
All reagents including primers are based on the LNA™
technology patented by Exiqon, Denmark and commer-
cially obtained from Exiqon, Denmark. The reactions
were performed on a Bio-Rad CFX384 (10 min at 95°C
with 45 amplification cycles at 95°C 10 s, 60°C 1 min,
ramp-rate 1.6°C/s optical read), according to the manufac-
turer’s instructions (all reagents from Exiqon, Denmark).
To adjust for run-to-run variations, an interplate cali-
brator assay called UniSp3 in which both primers and
DNA are present in the well was used. Only miRNAs
present in all groups and in 60% of the samples within a
group were included. Outlier detection was performed
with Grubb’s test with a confidence level of 0.95
and cut-off SD of 0.25. Samples with Ct values over 37
were considered background and excluded from further
analysis.
The qPCR data were analyzed using the 2–ΔCt quanti-
tative method [40], where ΔCt = Ct target - Ct global mean.
Normalization was performed to a global mean—i.e., the
average of all microRNAs expressed in all samples with
a Ct above 34 [41]—using the GenEX Pro 11 software
(Multid analyses, Sweden). Data were analyzed with
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formed with Ward’s algorithm and Euclidian distance
measurements.
Technical confirmation of the candidate miRNAs from
the miRNAome screen was carried out in triplicate using
the same RNA template and primers as for the screen.
The primers are based on Exiqon’s patented LNA™ tech-
nology and all primers were commercially obtained from
Exiqon, Denmark. The reactions were performed in a
96-well plate-format (Pick-&-Mix panel from Exiqon) on
a Roche Lightcycler 480 (10 min at 95°C, 45 amplifica-
tion cycles at 95°C 10 s, 60°C 1 min, ramp-rate 1.6°C/s
optical read), according to the manufacturer’s instruc-
tions. Samples with Ct values over 37 were considered
background and excluded from further analysis. Expres-
sion was normalized to miR-103 as suggested by the
“Norm-finder” algorithm, a model-based variance esti-
mation predicting the stability of a given miRNA
across samples [42]. The selection of miR-103 for
normalization was made by subjecting the data from
the technical confirmation to the “Norm-finder” algo-
rithm. The qPCR data for the technical confirmation
were analyzed using the 2–ΔΔCt quantitative method
[40] where ΔΔCt = (Ct target - Ct miR-103)SAH - (Ct target -
Ct miR-103)Sham and statistically evaluated by one-way
ANOVA followed by Student’s t-tests.
RNA from 50 μl serum was purified using the Serum
NucleoSpin miRNA kit (Macherey-Nagel, Germany)
as described by the manufacturer. RNA quality was
assessed with an Agilent RNA 6000 Nano Kit on a 2100
Bioanalyzer (Agilent, USA) and RNA was converted to
cDNA using the Universal cDNA synthesis kit at 60 min
at 42°C and 5 min at 95°C, and cooled to 4°C. qPCR was
performed using Pick-&-Mix panels with primers for 22
miRNAs. The reactions were performed on an ABI 7500
Fast (10 min at 95°C, 45 amplification cycles at 95°C
10 s, 60°C 1 min, ramp-rate 1.6°C/s optical read), ac-
cording to the manufacturer’s instructions (all reagents
from Exiqon, Denmark). Normalization was performed
to miR-103a-3p, miR-107, miR-181a-3p, miR-181a-5p,
miR24-3p, miR-451a, let-7i-5p, and miR23-3p. Differences
between groups were tested with one-way ANOVA.
Additional file
Additional file 1: 482 miRNAs expressed in cerebral vessels of both
sham and SAH rats at 1, 6, and 24 h post-operation.
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